Leerink Partnrs Has Negative Forecast for PRCT Q1 Earnings

PROCEPT BioRobotics Co. (NASDAQ:PRCT) – Investment analysts at Leerink Partnrs cut their Q1 2025 earnings per share (EPS) estimates for shares of PROCEPT BioRobotics in a research note issued on Tuesday, February 25th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings of ($0.47) per share for the quarter, down from their previous estimate of ($0.33). The consensus estimate for PROCEPT BioRobotics’ current full-year earnings is ($1.75) per share. Leerink Partnrs also issued estimates for PROCEPT BioRobotics’ Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.47) EPS, FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.57) EPS and FY2028 earnings at $0.03 EPS.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). The firm had revenue of $68.24 million for the quarter, compared to analyst estimates of $66.79 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%.

Several other equities research analysts also recently issued reports on PRCT. Morgan Stanley lowered their price target on PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a report on Wednesday. Truist Financial reissued a “buy” rating and set a $90.00 target price (down from $105.00) on shares of PROCEPT BioRobotics in a research note on Wednesday. Jefferies Financial Group started coverage on shares of PROCEPT BioRobotics in a research note on Thursday, November 14th. They issued a “hold” rating and a $95.00 price target on the stock. Finally, Wells Fargo & Company reissued an “overweight” rating and set a $112.00 price objective on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $94.29.

PROCEPT BioRobotics Price Performance

PRCT opened at $65.02 on Friday. The company has a fifty day simple moving average of $75.25 and a 200 day simple moving average of $79.94. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. The stock has a market cap of $3.39 billion, a P/E ratio of -33.34 and a beta of 1.03. PROCEPT BioRobotics has a 12 month low of $45.20 and a 12 month high of $103.81.

Insiders Place Their Bets

In related news, EVP Alaleh Nouri sold 28,092 shares of the stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $97.13, for a total transaction of $2,728,575.96. Following the completion of the transaction, the executive vice president now owns 52,472 shares in the company, valued at approximately $5,096,605.36. This represents a 34.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Reza Zadno sold 26,423 shares of PROCEPT BioRobotics stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $97.22, for a total transaction of $2,568,844.06. Following the completion of the sale, the chief executive officer now owns 152,762 shares in the company, valued at $14,851,521.64. The trade was a 14.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 17.40% of the company’s stock.

Institutional Trading of PROCEPT BioRobotics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Raleigh Capital Management Inc. bought a new stake in shares of PROCEPT BioRobotics during the 4th quarter worth approximately $32,000. Thematics Asset Management bought a new stake in PROCEPT BioRobotics during the fourth quarter worth $46,000. Signaturefd LLC lifted its stake in PROCEPT BioRobotics by 26.7% in the fourth quarter. Signaturefd LLC now owns 689 shares of the company’s stock valued at $55,000 after acquiring an additional 145 shares during the last quarter. IFP Advisors Inc bought a new position in shares of PROCEPT BioRobotics in the 4th quarter valued at about $58,000. Finally, Arcadia Investment Management Corp MI acquired a new position in shares of PROCEPT BioRobotics during the 4th quarter worth about $64,000. Institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).